Navigation Links
Stiefel Laboratories Appoints First Chief Scientific Officer

CORAL GABLES, Fla., April 7, 2008 /PRNewswire/ -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced Gavin Corcoran, M.D., FACP, has been promoted to the newly created position of chief scientific officer.

Creating the position of chief scientific officer will reinforce the already critical role played by the R&D organization and the unity between all R&D departments. It also will further strengthen the collaboration among Stiefel's five R&D facilities around the world.

As chief scientific officer, Corcoran will oversee global scientific and operational activities related to product development and support; medical and scientific affairs; clinical and pre-clinical research; pharmacovigilance; portfolio planning; and regulatory affairs.

"Gavin's promotion to chief scientific officer is a testament to the wonderful work he has done for Stiefel since he came on board," said Brent Stiefel, executive vice president, Global Corporate Development and Product Portfolio. "We chose Gavin to lead our R&D division because his vast experience along with his keen understanding of the industry arms him with the insight that will improve today's skin treatments and develop tomorrow's solutions."

The accomplishments Stiefel references include Corcoran establishing global R&D headquarters in Research Triangle Park, North Carolina; helping to lead integration following the acquisition of Connetics Corporation; overseeing R&D facilities on four continents; and strengthening the alignment of the R&D objectives and structure with the strategic direction of the business.

Prior to his promotion, Corcoran served as senior vice president, Global Research and Development. He joined Stiefel in 2005 as senior vice president, Global Clinical and Regulatory Affairs and has been a driving force in advancing the expansion of a world-class, global research and development organization. With this promotion, Corcoran will remain in Stiefel's R&D headquarters in Research Triangle Park and continue to report to Brent Stiefel.

Corcoran is a physician with specialties in internal medicine and infectious diseases and professional experience in private practice, academia and the pharmaceutical industry. A native of South Africa, he attended medical school at the University of the Witwatersrand in Johannesburg. His extensive pharmaceutical experience includes clinical research and regulatory leadership positions at Bayer, Schering-Plough and Amgen. In addition, he has successfully worked on drug development in a variety of fields, including anti-infectives, diabetes and dermatological infections.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%) available in the Duac(R) Care System (CS); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, 0.05% and Olux-E(TM) (clobetasol propionate) Foam, 0.05% also available in the Olux(R) / Olux-E(TM) COMPLETE PACK; Soriatane(R) (acitretin) Capsules available in the Soriatane(R) CK CONVENIENCE KIT; Verdeso(TM) (desonide) Foam, 0.05%; Brevoxyl(R)-4 Creamy Wash (benzoyl peroxide 4%) and Brevoxyl(R)-8 Creamy Wash (benzoyl peroxide 8%) packaged in the Brevoxyl(R) Acne Wash Kit; Extina(R) (ketoconazole) Foam, 2%; Oilatum(R) Cleansing Bar; Physiogel(R); Stieprox(R) (ciclopirox olamine); REVALESKIN(TM); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit

SOURCE Stiefel Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stiefel Laboratories, Inc. Appoints New President
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
7. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
8. Mesa Laboratories Names New Vice President of Sales and Marketing
9. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
10. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
11. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
Post Your Comments:
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ ... in utilization of hospital and nonhospital care, according to a recent study by the ... Louisiana, 16th Edition , found medical payments per claim with more than seven days ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology: